Diamond Eagle is still a question mark…it doesn’t want to leave the nest.
Health Sciences (HSAC) is expected to price their SPAC tonight and possibly Diamond Eagle (DEAC) too. However, Diamond Eagle, Jeff Sagansky’s fifth “Eagle”, was widely reported to be pricing last night, but sometimes the calendar (and the SEC) have other plans. So what are the odds it prices? 50/50 shot. The underwriters will make every effort, but it’s a toss up if they haven’t cleared with the SEC yet.
On the other hand, Health Sciences, the RTW Investments-backed SPAC focusing on BioPharma and Med Tech companies in North America and Europe, is pretty much a lock to go asap. HSAC, while SPAC newbies, has a compelling sector focus and the sponsor and management team are strong. Consequently, there should be significant demand for this deal. Especially since it’s a smaller size at $100 million. Allocations should be tight so look for this one to trade well right out of the gate.
As a reminder, a summary of terms for both SPACs is provided below: